An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1860-1868

  Ramchandani, Divya ^a   Weber, Georg F ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

Cancer progression; Gene expression; Polymorphism; Promoter

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; OSTEOPONTIN; PROGESTERONE RECEPTOR; RNA;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER GENETICS; CANCER GRADING; CONTROLLED STUDY; DNA DETERMINATION; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGESTERONE RECEPTOR NEGATIVE BREAST CANCER; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

BASE SEQUENCE; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84882677438     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2632     Document Type: Article

References (38)

1. Weber GF and Ashkar S: Stress response genes: the genes that make cancer metastasize. J Mol Med 78: 404-408, 2000.
2. Weber GF: Molecular mechanisms of metastasis. Cancer Lett 270: 181-190, 2008.
3. Weber GF, Lett S and Haubein N: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861-869, 2010.
4. Weber GF, Lett GS and Haubein NC: Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep 25: 433-441, 2011.
5. Weber GF: The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 8: 263-288, 2011.
6. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B and Weber GF: Osteopontin-c is a selective marker for breast cancer. Int J Cancer 122: 889-897, 2008.
7. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ and Arafat HA: Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146: 232-240, 2009.
8. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber GF and Gimba ER: Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 9: 280-293, 2011.
9. He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25: 2192-2202, 2006.
10. Senger DR, Asch BB, Smith BD, Perruzzi CA and Dvorak HF: A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 302: 714-715, 1983.
11. Noda M, Yoon K, Prince CW, Butler WT and Rodan GA: Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type β transforming growth factor. J Biol Chem 263: 13916-13921, 1988.
12. Chambers AF, Behrend EI, Wilson SM and Denhardt DT: Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res 12: 43-47, 1992.
13. Zhang G, He B and Weber GF: Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 23: 6507-6519, 2003.
14. Whalen KA, Weber GF, Benjamin TL and Schaffhausen BS: Polyomavirus middle T antigen induces the transcription of osteopontin, a gene important for migration of transformed cells. J Virol 82: 4946-4954, 2008.
15. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G and Ravazzolo R: Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 20: 87-96, 2004.
16. Hummelshoj T, Ryder LP, Madsen HO, Odum N and Svejgaard A: A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol 43: 980-986, 2006.
17. Deng QL, Ishii S and Sarai A: Binding site analysis of c-Myb: screening of potential binding sites by using the mutation matrix derived from systematic binding affinity measurements. Nucleic Acids Res 24: 766-774, 1996.
18. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G and Kunz M: The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 48: 14-23, 2009.
19. Zhao F, Chen X, Meng T, Hao B, Zhang Z and Zhang G: Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 12: 477, 2012.
20. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Janssen M, Zawaideh S, Rittling S, Denhardt DT, Glimcher MJ and Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864, 2000.
21. Shaker OG, Sadik NA and El-Dessouki A: Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C. Hum Immunol 73: 1039-1045, 2012.
22. Mochida S, Hashimoto M, Matsui A, Naito M, Inao M, Nagoshi S, Nagano M, Egashira T, Mishiro S and Fujiwara K: Genetic polymorphisms in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 313: 1079-1085, 2004.
23. Cheema BS, Iyengar S, Ahluwalia TS, Kohli HS, Sharma R, Shah VN, Bhansali A, Sakhuja V and Khullar M: Association of an Osteopontin gene promoter polymorphism with susceptibility to diabetic nephropathy in Asian Indians. Clin Chim Acta 413: 1600-1604, 2012.
24. Trivedi T, Franek BS, Green SL, Kariuki SN, Kumabe M, Mikolaitis RA, Jolly M, Utset TO and Niewold TB: Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus. J Biomed Biotechnol 2011: 802581, 2011.
25. Jiang Y, Yao M, Liu Q and Zhou C: OPN gene polymorphisms influence the risk of knee OA and OPN levels in synovial fluid in a Chinese population. Arthritis Res Ther 15: R3, 2013.
26. Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, Egashira T, Hashimoto M, Mishiro S, Mochida S and Fujiwara K: SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 40: 381-388, 2005.
27. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N and Zhang J: Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32: 410-416, 2005.
28. Gao B, Yasui T, Itoh Y, Li Z, Okada A, Tozawa K, Hayashi Y and Kohri K: Association of osteopontin gene haplotypes with nephrolithiasis. Kidney Int 72: 592-598, 2007.
29. Gögebakan B, Igci YZ, Arslan A, Igci M, Erturhan S, Oztuzcu S, Sen H, Demiryürek S, Arikoglu H, Cengiz B, Bayraktar R, Yurtseven C, Sarica K and Demiryürek AT: Association between the T-593A and C6982T polymorphisms of the osteopontin gene and risk of developing nephrolithiasis. Arch Med Res 41: 442-448, 2010.
30. Schmidt-Petersen K, Brand E, Telgmann R, Nicaud V, Hagedorn C, Labreuche J, Dördelmann C, Elbaz A, Gautier-Bertrand M, Fischer JW, Evans A, Morrison C, Arveiler D, Stoll M, Amarenco P, Cambien F, Paul M and Brand-Herrmann SM: Osteopontin gene variation and cardio/cerebrovascular disease phenotypes. Atherosclerosis 206: 209-215, 2009.
31. Hendig D, Arndt M, Szliska C, Kleesiek K and Götting C: SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum. Clin Chem 53: 829-836, 2007.
32. Pegoraro E, Hoffman EP, Piva L, Gavassini BF, Cagnin S, Ermani M, Bello L, Soraru G, Pacchioni B, Bonifati MD, Lanfranchi G, Angelini C, Kesari A, Lee I, Gordish-Dressman H, Devaney JM, McDonald CM; Cooperative International Neuromuscular Research Group: SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 76: 219-226, 2011.
33. de las Fuentes L, Gu CC, Mathews SJ, Reagan JL, Ruthmann NP, Waggoner AD, Lai CF, Towler DA and Dávila-Román VG: Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness. J Am Soc Echocardiogr 21: 954-960, 2008.
34. Marciano R, D'Annunzio G, Minuto N, Pasquali L, Santamaria A, Di Duca M, Ravazzolo R and Lorini R: Association of alleles at polymorphic sites in the osteopontin encoding gene in young type 1 diabetic patients. Clin Immunol 131: 84-91, 2009.
35. D'Alfonso S, Barizzone N, Giordano M, Chiocchetti A, Magnani C, Castelli L, Indelicato M, Giacopelli F, Marchini M, Scorza R, Danieli MG, Cappelli M, Migliaresi S, Bigliardo B, Sabbadini MG, Baldissera E, Galeazzi M, Sebastiani GD, Minisola G, Ravazzolo R, Dianzani U and Momigliano-Richiardi P: Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52: 539-547, 2005.
36. Chen J, Wu Q, Lu Y, Xu T, Huang Y, Ribas J, Ni X, Hu G, Huang F, Zhou L and Lu D: SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet 55: 456-461, 2010.
37. Barizzone N, Marchini M, Cappiello F, Chiocchetti A, Orilieri E, Ferrante D, Corrado L, Mellone S, Scorza R, Dianzani U and D'Alfonso S: Association of osteopontin regulatory polymorphisms with systemic sclerosis. Hum Immunol 72: 930-934, 2011.
38. Nakayama H, Nagai H, Matsumoto K, Oguro R, Sugimoto K, Kamide K, Ohishi M, Katsuya T, Okamoto H, Maeda M, Komamura K, Azuma J, Rakugi H and Fujio Y: Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese population. Hypertens Res 34: 1141-1146, 2011.